Patent ID: 8563323

Claim:
A method of predicting response to therapy in a patient with acute myeloid leukemia (AML) comprising: (a) performing mass spectrometry on a plasma sample from a patient to generate a protein spectra comprising protein peaks; (b) identifying a protein peak or group of protein peaks in the protein spectra corresponding to one or more proteins having a mass-to-charge ratio of 895.5696, 2274.7727, 22130.579, 5076.1814, 353.8245, 14616.859, 8127.5061, 226.097, 6873.2851, 2533.253, 15269.21, 16424.51, 8330.896, 2509.468, 9925.422, 22130.58, 41.8358, 49877.3113, 10127.7946, 8335.7003, 5649.4968, 531.8963, 9040.0205, 65.0937, 86.7774, 12241.7091, 11411.8902, 7361.645, 11060.4231, 37411.921, 3067.3973, 39008.5589, 48423.466, 5719.3364, 10680.7025, or 8206.4623; and (c) predicting the patient's response to therapy based on the identification of one or more of the protein peaks.